Skip to main content

Table 1 Patient characteristics.

From: A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis

  700 mg NAC 2800 mg NAC
Number of patients 11 10
Male/female (n) 9/2 7/3
Age 27.0 (21.0 - 35.0) 28.5 (24.0 - 35.0)
Height (cm) 168.0 (163.0 - 178.0) 174.0 (168.0 - 178.0)
Weight (kg) 65.5 (59.0 - 70.40) 64.5 (57.4 - 72.0)
Pseudomonas aeruginosa 4 3
Staphylococcus aureus 1 1
Various bacteria/saprophytic flora 6 6
FEV1 (% pred) 80.6 (55.3 - 90.0) 65.8 (62.9 - 73.4)
FVC (% pred) 82.6 (78.4 - 100.4) 84.8 (79.6 - 91.2)
MEF25-75 (% pred) 41.1 (12.4 - 68.1) 21.6 (19.6 - 27.9)
  1. Data are shown as median (25 - 75%) values